ABT-239
From Wikipedia, the free encyclopedia
 |
|
|
ABT-239
|
|
| Systematic (IUPAC) name | |
| 4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C22H22N2O |
| Mol. mass | 330.42 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
ABT-239 is an H3-receptor antagonist which is currently being investigated as a treatment for ADHD, Alzheimer's disease, and schizophrenia. ABT-239 is more active at the human H3 receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant.
[edit] References
- Pharmacological Properties of ABT-239: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties
- Pharmacological Properties of ABT-239: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
